MTL-CEBPA
- Generic Name
- MTL-CEBPA
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 33
- Registration Number
- NCT05097911
- Locations
- πΈπ¬
National University Hospital, Singapore, Singapore
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 150
- Registration Number
- NCT04710641
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΈπ¬National University Hospital Singapore, Singapore, Singapore
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 108
- Registration Number
- NCT04105335
- Locations
- π¬π§
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
π¬π§Imperial College Healthcare NHS Trust, London, United Kingdom
π¬π§Freeman Hospital, Newcastle Upn Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 75
- Registration Number
- NCT02716012
- Locations
- π¨π³
National Taiwan University Hospital, Taipei, Taiwan
π¬π§University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
π¬π§The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.